Free Alerts   Login
Energy › Oil, Gas Field Services, Nbc

CLB Stock Price Correlated With Core Laboratories NV Financials

CLB Stock Price vs. Quarterly
CLB
Income Statement
Cash Flow
Balance Sheet

CLB Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

CLB Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

CLB Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Ariel Investments
8,988,399 sh
-75,319 sh
-1%
$158,736
-$58,884
Blackrock.
7,979,470 sh
221,289 sh
3%
$140,918
-$45,356
Vanguard Group
5,364,333 sh
4,221 sh
0%
$94,734
-$33,963
Earnest Partners
3,727,668 sh
-53,944 sh
-1%
$65,831
-$24,966
Boston Trust Walden Corp
2,274,229 sh
-3,545 sh
0%
$40,163
-$14,526
State Street
2,041,533 sh
-36,791 sh
-2%
$36,053
-$13,848
Ameriprise Financial
1,089,207 sh
127,116 sh
13%
$19,235
-$3,865
Fred Alger Management
1,020,549 sh
-306,780 sh
-23%
$18,023
-$13,846
Geode Capital Management
1,000,731 sh
58,817 sh
6%
$17,675
-$4,943
Dimensional Fund Advisors
947,807 sh
75,684 sh
9%
$16,739
-$4,202
Royce & Associates Lp
914,274 sh
225,006 sh
33%
$16,146
-$403
Fisher Asset Management
753,555 sh
133,375 sh
22%
$13,308
-$1,583
Disciplined Growth Investors /Mn
752,367 sh
13,983 sh
2%
$13,287
-$4,442
Morgan Stanley
727,516 sh
40,232 sh
6%
$12,848
-$3,653
Van Eck Associates
586,432 sh
-121,436 sh
-17%
$10
-$7
Charles Schwab Investment Management
580,353 sh
-5,779 sh
-1%
$10,249
-$3,824
Northernrp
494,336 sh
-44,795 sh
-8%
$8,731
-$4,214
Bank Of New York Mellon
464,038 sh
97,784 sh
27%
$8,194
-$601
Invesco.
412,484 sh
-23,975 sh
-5%
$7,284
-$3,196
Citadel Advisors
357,900 sh
347,300 sh
3276%
$6,320
$6,065
COMPANY PROFILE
1. BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories N.V. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Core Laboratories N.V.'s balance sheet information for the year ended December 31, 2021 was derived from the 2021 audited consolidated financial statements. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements, and should be read in conjunction with the audited financial statements and the summary of significant accounting policies and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Annual Report"). Core Laboratories N.V. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interests have been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100 % owned. All inter-company transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three months ended March 31, 2022 may not necessarily be indicative of the results that may be expected for the year ending December 31, 2022. References to “Core Lab”, "Core Laboratories", the "Company", "we", "our" and similar phrases are used throughout this Quarterly Report on Form 10-Q and relate collectively to Core Laboratories N.V. and its consolidated subsidiaries. We operate our business in two reportable segments: (1) Reservoir Description and (2) Production Enhancement. These complementary segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of product types and services offered by these business segments, see Note 16, S egment Reporting . Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported net income or cash flows for the three months ended March 31, 2021 .

Free historical financial statements for Core Laboratories NV. See how revenue, income, cash flow, and balance sheet financials have changed over 49 quarters since 2011. Compare with CLB stock chart to see long term trends.

Data imported from Core Laboratories NV SEC filings. Check original filings before making any investment decision.